Catalyst Watch: Interim Clinical Trial Results Expected at Society of Vascular Surgery This Week

Research evidence excerpt

Catalyst Watch: Interim Clinical Trial Results Expected at Society of Vascular Surgery This Week

June 8, 2026 Humacyte, Inc.

(HUMA, Buy, $2 PT)MEDICAL Ryan Zimmerman

Catalyst Watch: Interim Clinical Trial Results Expected at Society of (212) 527-3586 rzimmerman@btig.com

Vascular Surgery This Week Iseult McMahon

(332) 400-5103 imcmahon@btig.com

WHAT YOU SHOULD KNOW: Ahead of HUMA's anticipated announcement of its Company Data

interim V012 Phase 3 trial results this Thursday, we are providing a summary of Closing Price $1.49

the ongoing trial. The upcoming interim readout represents a significant near-term

Price Target $2.00 catalyst for the company, focusing on the use of the ATEV for arteriovenous (AV) access

Market Cap (M) $294.79TECHNOLOGY in hemodialysis. This indication addresses a major unmet medical need, primarily

for female patients with end-stage renal disease (ESRD), and a positive outcome Enterprise Value (M) $158.13

could pave the way for an accelerated regulatory submission in 2H26. Assuming the Shares Out (M) 197.85

interim readout is positive, we see this submission as de-risked given this would be Avg Daily Vol-3 Months (M) 7.38

HUMA's second prospective randomized head-to-head study for the ATEV and that theEQUITY Revisions manufacturing process is the same as Trauma. In terms of timing, the ATEV's RMAT

designation allows for an accelerated review period (if granted), setting up the launch Previous Current

as early as mid-FY27. AV Access is a significantly larger market and opens up HUMA to Rating Buy Buy

a broader customer base relative to Trauma. Price Target $2.00 $2.00

■ Announcement of results: HUMA is scheduled to report top-line interim results FY26E REV 4.37 4.37

FY27E REV 24.33 24.33RESEARCH from the V012 Phase 3 trial on Thursday, June 11.